Whalesbook
Kya chal raha hai Novartis mein?
Dekho, Novartis ab ekdum 'pure-play innovator' banna chahta hai. Iske liye, unhone apni purani company Novartis India ka stake ₹1446 Crore mein bech diya hai. Lekin tension nahi, unki jo unlisted Healthcare arm hai, woh abhi bhi chalegi India mein, aur woh pure innovative medicines pe focus karenge.
India ab R&D ka Big Boss Banega?
Abhi tak India mein mostly late-stage clinical trials hote the, lekin Novartis ab yahan early-stage scientific discovery aur Phase I clinical studies bhi karega. Iska matlab hai ki ab Novartis ke liye India, Basel aur US ke saath global R&D hub ban jayega. Hyderabad aur Mumbai wale R&D centers bhi ab global infrastructure ka important hissa honge. Ye company kaafi ambitious hai, aur ab woh cardiovascular disease, oncology, aur immunology jaise core areas mein R&D ko badhava de rahe hain.
Pura Scene Kya Hai?
Yeh jo ₹1446 Crore ka deal hua hai, yeh February 2026 mein finalize hoga, jisme ChrysCapital jaise private equity firms bhi involved hain. Novartis ka aim hai ki woh sirf cutting-edge therapies pe focus karein. Is deal se unka global strategy align hota hai, jisme woh ek innovative medicines company banna chahte hain. India mein unke 9,000 se zyada log kaam kar rahe hain, aur woh yahan Inclisiran (cardiovascular) aur Pluvicto (prostate cancer) jaise drugs ki development mein help kar rahe hain.
Market mein Novartis kaafi competitive environment mein hai, jahan Pfizer, Roche jaise players hain. Lekin Novartis specialty biologics aur precision medicine pe focus kar raha hai. India ki government bhi R&D ko support kar rahi hai, jisse companies innovation pe zyada dhyan de sakein.
Brokerage firms ne filhaal 'Hold' rating di hai, aur average price target around $141.20 hai. Kuch analysts ko late-stage pipeline assets ko lekar chinta hai, aur kuch ko sales projections meet hone mein risk lagta hai. Lekin company ne India mein R&D pe commitment dikhaya hai, jo unke future growth ke liye important hai.